Galapagos NV (GLPG.BR)
10 Dec 2013
|Market Cap (Mil.):||€420.95|
|Shares Outstanding (Mil.):||29.79|
BRUSSELS, Nov 27 - Galapagos NV : * GSK to initiate exploratory Phase 2 study with GSK2586184 in patients with
BRUSSELS, Nov 12 - Belgian biotech group Galapagos said its unit Biofocus signed a 3-year research deal with U.S. firm Biogen Idec to find new treatments for scleroderma.
BRUSSELS, Oct 17 - Belgian biotech company Galapagos said on Thursday that it was set to start clinical trials on a possible treatment for cystic fibrosis at the end of 2014.
BRUSSELS - Belgian biotech firm Galapagos has signed a cooperation deal worth up to $405 million with U.S. company AbbVie to develop a new treatment for cystic fibrosis.
BRUSSELS, Aug 9 - Galapagos, the Belgian developer of drugs to fight autoimmune diseases such as lupus and rheumatoid arthritis, said it was on track to meet its full-year revenue guidance this year.
BRUSSELS, July 1 - Galapagos NV : * First patients screened for phase 2b studies with glpg0634
Earnings vs. Estimates
Analyst Research Reports
Galapagos NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.